Slide 1: Q3 FY25 Earnings Presentation
Q3 FY25 Earnings Presentation November 6, 2025 © Solventum 2025. All rights reserved.
Slide 2: Forward-looking statements and use of document
Forward-looking statements and use of document This presentation and other materials Solventum has filed or will file with the U.S. Securities & Exchange Commission (“SEC”) (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events a
Slide 3: Solventum's roadmap to the mission
Solventum’s roadmap to the mission Values Strategic pillars Put people first Be a best & preferred Mission place to work Win with excellence Enabling better, Solve what matters smarter, safer Be a trusted partner healthcare to Advance together improve lives Be a top quartile Live with heart performe
Slide 4: Solventum value creation formula
Solventum value creation formula Attractive set up diverse businesses, attractive markets and strong brands Foundational + enhancements mission, talent, culture, innovation engine (commercial and R&D) market selection and growth drivers – enable sales growth, + Strategic clarity margin expansion and
Slide 5: Key Messages for the Quarter
Key Messages Extending Meaningful for the Quarter Track Record Progress on of Execution Separation Announced Increased program to confidence expand ongoing in LRP transformation © Solventum 2025. All rights reserved. 5 2See non-GAAP financial measures and reconciliation schedules in the appendix of
Slide 6: Q3 FY25 Financial summary
Q3 FY25 Financial summary Dental Solutions $340M +8.4% Reported +6.5% Organic Key Metrics GAAP Non-GAAP3 Health Information TOTAL SOLVENTUM Systems SALES1 MedSurg Operating $345M margin 80.6% 20.6% $1,206M +5.9% Reported +5.6% Organic $2,096M +2.1% Reported +0.7% Y/Y Reported +1.1% Organic +2.7% Y/Y
Slide 7: MedSurg summary
MedSurg summary AWC $485M | 40% +3.5% Y/Y Rep +2.7% Y/Y Org $1,206M Q3 financial results +2.1% Y/Y Reported +1.1% Y/Y Organic IP&SS Q3 FY25 Q3 FY24 Y/Y $722M | 60% +1.2% Y/Y Rep Flat Y/Y Org Reported +2.1% Prevena Plus and V.A.C.® Peel Net sales $1,206M $1,182M Organic +1.1% and Place Dressing Singl
Slide 8: Dental Solutions summary
Dental Solutions summary Solventum Filtek Warmer Kit Composite Easy one-button operation warms Q3 financial results composite material in as little as 2 minutes with capacity for six capsules and one flowable syringe. Designed Q3 FY25 Q3 FY24 Y/Y especially for Filtek dental restoratives to achieve
Slide 9: Health Information Systems summary
Health Information Systems summary Solventum System 360 Encompass Latest generation coding solution Q3 financial results combines coding and reimbursement processes along with workflow improvements to help hospitals Q3 FY25 Q3 FY24 Y/Y streamline revenue cycle processes, receive accurate reimburseme
Slide 10: Purification & Filtration summary
Advancing portfolio Purification & Filtration summary optimization with sale of P&F segment Q3 financial results Transformative sale of P&F segment for ~$4B generated ~$3.6B of net Q3 FY25 Q3 FY24 Y/Y proceeds, of which $2.7B were applied to debt paydown. Reported –28.7% Net sales $128M $180M Organi
Slide 11: FY2025 financial guidance and considerations
FY2025 financial guidance and Additional considerations considerations P&F Sale FY2025 annual guidance incudes P&F for historical results through the deal close on Sept. 1, 2025 Sales for the retained Drinking Water Filtration Increasing to high-end of range business are captured in ‘All Other’ Orga
Slide 12: Appendix
Appendix © Solventum 2025. All rights reserved. 12
Slide 13: Non-GAAP financial measures
Non-GAAP financial measures In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adj
Slide 14: Q3 FY25 non-GAAP reconciliation & free cash flow
Q3 FY25 non-GAAP reconciliation & free cash flow Purification 3M Spin-off & Separation- Certain Litigation- and Filtration Separation- Loss on Debt ($ Millions, except per share data) Q3 FY25 GAAP Amortization Restructuring related Costs related Costs related Gain on Sale of Business Extinguishment,
Slide 15: Glossary and definitions
Glossary and definitions Abbreviation Elaboration Organic sales growth AWC Advanced Wound Care Total net sales less the impacts of foreign currency and sales from business acquisitions or divestitures for the first 12 months post-transaction FCF Free cash flow Adjusted operating income Operating inc